scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
September 19, 2023 08:00 ET
|
scPharmaceuticals, Inc.
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency...
scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 03, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion
August 01, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
June 23, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...